Lyophilized pharmaceutical composition of neocarzinostatin derivative
US5026772A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 29, 1988 |
| Grant date | Jun 25, 1991 |
| Priority date | — |
| Expiry date | Aug 29, 2008 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/58
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A lyophilized pharmaceutical composition comprised of a neocarzinostatin derivative having the formula (SMA)-(NCS)-(SMA), is made by a method including dissolving the neocarzinostatin derivative and stabilizing agent comprising at least one saccharide selected from the group consisting of monosaccharides, disaccharides and dextran in an aqueous buffer solution having a pH ranging from about 7.5 to about 9.5, the stabilizing agent being present in an amount by weight (titer) which is at least equal to that of the neocarzinostatin derivative, to provide a solution; adjusting the pH of the solution to provide a pH-adjusted solution having a pH of about 8.0.+-.0.5; sterilizing the pH-adjusted solution by filtration to provide a sterilized solution; and lyophilizing the sterilized solution.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.